Current HIV/AIDS Reports

, Volume 4, Issue 3, pp 141–146

Preventing bacterial disease in the HIV-infected of sub-saharan africa: The role of cotrimoxazole and the pneumococcal vaccines

Article

Abstract

Bacterial infection is a major cause of morbidity and mortality among patients with HIV living in Africa. Broadening the scope of cotrimoxazole (CTX) prophylaxis to cover patients whose CD4 counts are above 200 cells/mm3 has been suggested as a means of improving the control of infectous disease on the continent. CTX has demonstrated antimalarial benefit in Central and West Africa, but in areas of high bacterial resistance to CTX, the prophylactic role of CTX as an antibacterial agent is less clear. In particular there is little to suggest that prophylactic CTX provides reliable control against the pneumococcus. In both South Africa and the Gambia, several clinical studies with pneumococcal conjugate vaccines have resulted in improved clinical outcomes for children with and without HIV infection. There is clearly much more that needs to be done, and conjugate vaccines provide a unique opportunity to improve the future lives of Africa’s children

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Groenewald P, Nannan N, Bourne D, et al.: Identifying deaths from AIDS in South Africa. AIDS 2005, 19:193–201.PubMedCrossRefGoogle Scholar
  2. 2.
    Simelela NP: National Antiretroviral Treatment Guidelines for South Africa. National Department of Health. Pretoria, South Africa: Jacana; 2004:3.Google Scholar
  3. 3.
    Badri M, Lawn SD, Wood R: Short-term risk of AIDS or death in people infected with HIV-1 before antiretroviral therapy in South Africa: a longitudinal study. Lancet 2006, 368:1254–1259PubMedCrossRefGoogle Scholar
  4. 4.
    Corbett EL, Churchyard GJ, Charalambos S, et al.: Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002, 34:1251–1258.PubMedCrossRefGoogle Scholar
  5. 5.
    Chintu C, Mudenda V, Lucas S, et al.: Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002, 360:985–990.PubMedCrossRefGoogle Scholar
  6. 6.
    Watera C, Todd J, Muwonge R, et al.: Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr 2006, 42:373–378.PubMedGoogle Scholar
  7. 7.
    Anglaret X, Toure S, Ouassa T, et al.: Thresholds of CD4 cells for initiating trimethoprim-sulfamethoxazole prophylaxis in west Africa [research letter]. AIDS 2000, 14:2628–2629.PubMedCrossRefGoogle Scholar
  8. 8.
    Sinha A, Levine O, Knoll MD, Lieu TA: Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389–396.PubMedCrossRefGoogle Scholar
  9. 9.
    Whitney CG, Pilishvili T, Farley MM, et al.: Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495–1502.PubMedCrossRefGoogle Scholar
  10. 10.
    Huovinen P: Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001, 32:1608–1614.PubMedCrossRefGoogle Scholar
  11. 11.
    Masters PA, O’Bryan TA, Zurlo J, et al.: Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003, 163:402–410.PubMedCrossRefGoogle Scholar
  12. 12.
    Roper C, Pearce R, Bredenkamp B, et al.: Antifolate antimalarial resistance in southeast Africa: a population-based analysis. Lancet 2003, 361:1174–1181.PubMedCrossRefGoogle Scholar
  13. 13.
    Feikin DR, Dowell SF, Nwanyanwu OC, et al.: Increased carriage of trimethoprim-supfamethoxazole resistant Streptococcus pneumoniae in Malawian children after treatment with sulfadoxine-pyrimethamine. J Infect Dis 2000, 181:1501–1505.PubMedCrossRefGoogle Scholar
  14. 14.
    Ma L, Borio L, Masur H, Kovacs JA: Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprimsulfamethoxazole or daspone use. J Infect Dis 1999, 180:1969–1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Ruffini DD, Madhi SA: The high burden of Pneumocystis carinii pneumonia in Africa HIV-1-infected children hospitalized for severe pneumonia. AIDS 2002, 16:105–112.PubMedCrossRefGoogle Scholar
  16. 16.
    Anglaret X, Chene G, Attia A, et al.: Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d’Ivoire: a randomized trial. Lancet 1999, 353:1463–1468.PubMedCrossRefGoogle Scholar
  17. 17.
    Wiktor SZ, Sassan-Morokro M, Grant AD, et al.: Efficacy of trimethoprim-sulfamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abijan, Cote d’Ivoire: a randomized controlled trial. Lancet 1999, 353:1469–1475.PubMedCrossRefGoogle Scholar
  18. 18.
    Mermin J, Lule J, Ekwaru JP, et al.: Effect of co-trimoxazole prophylaxis, morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004, 364:1428–1434.PubMedCrossRefGoogle Scholar
  19. 19.
    Mermin J, Lule J, Ekwaru JP, et al.: Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. AIDS 2005, 19:1035–1042.PubMedCrossRefGoogle Scholar
  20. 20.
    Mermin J, Ekwaru JP, Liechty CA, et al.: Effect of cotrimoxazole, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006, 367:1256–1261.PubMedCrossRefGoogle Scholar
  21. 21.
    Mermin J, Lule JR, Ekwaru JP, Pitter C: Should cotrimoxaozle prophylaxis be taken by all adults with HIV in Africa? AIDS 2005, 19:845–846.PubMedGoogle Scholar
  22. 22.
    Chintu C, Bhat GJ, Walker AS, et al.: Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomized placebo-controlled trial. Lancet 2004, 364: 1865–1871.PubMedCrossRefGoogle Scholar
  23. 23.
    Fisk DT, Mesnick S, Kazazjian PH: Pneumocystic carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003, 36:70–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Madhi SA, Cutland C, Ismail K, et al.: Ineffectiveness of trimethoprim-sulfamethoxazole prophylax is and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis 2002, 35:1120–1126.PubMedCrossRefGoogle Scholar
  25. 25.
    Walter J, Mwiya M, Scott N, et al.: Cotrimoxazole prophylaxis and adverse birth outcomes among HIV-infected women in Lusaka, Zambia [abstract 126]. Paper presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO; February 5–8, 2006.Google Scholar
  26. 26.
    Grimwade K, Sturm AW, Nunn AJ, et al.: Effestiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005, 19:163–168.PubMedCrossRefGoogle Scholar
  27. 27.
    World Health Organization: WHO expert consultation on cotrimoxazole prophylaxis in HIV infection, http://www.who.int/hiv/pub/meetingreports/ctxprophylaxismeeting.pdf. Accessed May 4, 2007.
  28. 28.
    Anglaret X: Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa. Lancet 2001, 358:1027–1028.PubMedCrossRefGoogle Scholar
  29. 29.
    Mermin J, Bunnell R, Lule J, et al.: Developing an evidence-based preventive care package for persons with HIV in Africa. Trop Med Internat Health 2005, 10:961–970.CrossRefGoogle Scholar
  30. 30.
    Corbett EL, Steketee RW, ter Kuile FO, et al.: HIV/AIDS and the control of other infectious diseases in Africa. Lancet 2002, 359:2177–2187.PubMedCrossRefGoogle Scholar
  31. 31.
    Jordano Q, Falco V, Almrante B, et al.: Invasive pneumococcal disease in patients in fected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623–1628.PubMedCrossRefGoogle Scholar
  32. 32.
    Dworkin MS, Williamson J, Jones JL, et al.: Prophylaxis with trimethoprim-sulfamethoxazole for human immunodeficiency virus-infected patients: impact on risk for infectious diseases. Clin Infect Dis 2001, 33:393–398.PubMedCrossRefGoogle Scholar
  33. 33.
    Watera C, Nakiyingi J, Miiro G, et al.: 23-Valent pneumococal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS2004, 18:1210–1213.Google Scholar
  34. 34.
    Gordon SB, Chaponda M, Walsh AL, et al.: Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-tern survival. AIDS 2002, 16:1409–1417.PubMedCrossRefGoogle Scholar
  35. 35.
    Hill PC, Akisanya A, Sankareh K, et al.: Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Villagers. Clin Infect Dis 2006, 43:673–679.PubMedCrossRefGoogle Scholar
  36. 36.
    Klugman KP, Madhi SA, Huebner RE, et al.: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349:1314–1318.CrossRefGoogle Scholar
  37. 37.
    Cutts FT, Zaman SMA, Enwere G, et al.: Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in the Gambia: randomized, double-blind, placebo-controlled trial. Lancet 2005, 365:1139–1146.PubMedCrossRefGoogle Scholar
  38. 38.
    Madhi SA, Kuwanda L, Cutland C, Klugman KP: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and uninfected children. Clin Infect Dis 2005, 40:1511–1518.PubMedCrossRefGoogle Scholar
  39. 39.
    Levine OS, O’Brien KL, Knoll M, et al.: Pneumococcal vaccination in developing countries. Lancet 2006, 367:1880–1882.PubMedCrossRefGoogle Scholar
  40. 40.
    Whitney CG, Schaffner W, Butler JC: Rethinking recommendations for use of pneumococcal vaccines in adults. Clin Infect Dis 2001, 33:662–675.PubMedCrossRefGoogle Scholar
  41. 41.
    Dworkin MS, Ward JW, Hanson DL, et al.: Pneumococcal disease among the human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination. Clin Infect Dis 2001, 32:794–800.PubMedCrossRefGoogle Scholar
  42. 42.
    Gilks CF, Ojoo SA, Ojoo JC, et al.: Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex workers in Nairobi, Kenya. Lancet 1996, 347:718–723.PubMedCrossRefGoogle Scholar
  43. 43.
    French N, Nakiyingi J, Carpenter LM, et al.: 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected Ugandan adults: double-blind, randomized and placebocontrolled trial. Lancet 2000, 355:2106–2111.PubMedCrossRefGoogle Scholar
  44. 44.
    Benson CA, Kaplan JE, Masur H, et al.: Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. Clin Infect Dis 2005, 40:S151.CrossRefGoogle Scholar
  45. 45.
    Mofenson LM, Oleske J, Serchuck L, et al.: Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Clin Infect Dis 2005, 40:S20.CrossRefGoogle Scholar
  46. 46.
    Long SS: Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine [editorial]. Clin Infect Dis 2005, 41:30–34.PubMedCrossRefGoogle Scholar
  47. 47.
    Giebink GS: The prevention of pneumococcal disease in children. N Engl J Med 2001, 345:1177–1183.PubMedCrossRefGoogle Scholar
  48. 48.
    Greenwood B: Interpreting vaccine efficacy [editorial]. Clin Infect Dis 2005, 40:1519–520.PubMedCrossRefGoogle Scholar
  49. 49.
    Kyaw MH, Lynfield R, Schaffner W, et al.: Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455–1463.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Brien KL, Moulton LH, Reid R, et al.: Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomized trial. Lancet 2003, 362:355–361.PubMedCrossRefGoogle Scholar
  51. 51.
    Byington CL, Samore MH, Stoddard GJ, et al.: Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain West: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21–29.PubMedCrossRefGoogle Scholar
  52. 52.
    Whitney CG, Farley MM, Hadler J, et al.: Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737–1746.PubMedCrossRefGoogle Scholar
  53. 53.
    Talbot TR, Poehling KA, Hartert TV, et al.: Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004, 39:641–648.PubMedCrossRefGoogle Scholar
  54. 54.
    Mbelle N, Huebner RE, Wasas AD, et al.: Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999, 180:1171–1178.PubMedCrossRefGoogle Scholar
  55. 55.
    Recommended childhood and adolescent immunization schedule, United States, 2006. MMWR 2006, 54:Q1–Q4.Google Scholar
  56. 56.
    Musher DM: Pneumococcal vaccine—direct and indirect (“herd”) effects [editorial]. N Engl J Med 2006, 354:1522–1524.PubMedCrossRefGoogle Scholar
  57. 57.
    Porat N, Arguedas A, Spratt BG, et al.: Emergence of penicillin-nonsusceptible Streptococcus pneumoniae clones expressing serotypes not present in the antipneumococcal conjugate vaccine. J Infect Dis 2004, 190:2154–2162.PubMedCrossRefGoogle Scholar
  58. 58.
    Lebel MH, Kellner JD, Ford-Jones EL, et al.: A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin Infect Dis 2003, 36:259–268.PubMedCrossRefGoogle Scholar
  59. 59.
    Black RE, Morris SS, Bryce J: Where and why are 10 million children dying every year? Lancet 2003, 361:2226–2234.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Toga Laboratory and Kimera ConsultantsMeadowdale, JohannesburgSouth Africa

Personalised recommendations